IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories, Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
IDEXX Laboratories reads as neutral right now, with no clear lean either way.
- What's working
- It turns sales into profit more efficiently than most other healthcare companies.
- Worth watching
- You're paying more for it than for most other healthcare companies, relative to what it earns.
Analyst price target
~12-month · 12 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy…
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 11,000
- Headquarters
- Westbrook, ME
Similar stocks
What’s behind the score
Valuation
P/E 39.4 — lower than 29% of Healthcare peers
P/B 27.4 — lower than 4% of Healthcare peers
P/S 9.7 — lower than 13% of Healthcare peers
EV/EBITDA 27.8 — lower than 7% of Healthcare peers
EV/Revenue 9.9 — lower than 10% of Healthcare peers
PEG 3.1 — lower than 0% of Healthcare peers
FCF yield 2.1% — higher than 14% of Healthcare peers
Profitability & quality
Gross margin 62.4% — higher than 47% of Healthcare peers
Operating margin 35.0% — higher than 87% of Healthcare peers
Net margin 25.0% — higher than 87% of Healthcare peers
ROE 74.2% — higher than 93% of Healthcare peers
ROA 27.1% — higher than 100% of Healthcare peers
Free cash flow is 80% of reported net income
Financial health
Debt/equity 0.7 — lower than 48% of Healthcare peers
Current ratio 1.17 — higher than 24% of Healthcare peers
Quick ratio 0.73 — higher than 28% of Healthcare peers
Cash/debt 0.18 — higher than 41% of Healthcare peers
Debt/EBITDA 0.68 — lower than 83% of Healthcare peers
Growth
Revenue growth 9.7% YoY — higher than 60% of Healthcare peers
Earnings growth 17.6% YoY — higher than 50% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Net insider buying, +1.4% of insider shares
Institutions net sold, -15.0% of shares held
Insiders hold 0.2% of shares outstanding
2.8% of float sold short
Momentum
Mixed vs its moving averages
22% of the way from its 52-week low to high